Regulatory News:
Ipsen (Paris:IPN) announced the appointment, of Dominique Bridon
as Vice-President, Discovery of the Ipsen Group, effective today. He
will report to Jacques-Pierre Moreau, Ipsen´s Executive Vice
President, Chief Scientific Officer. Based in the research center of
Ipsen in Boston, he will be have under his responsibility the drug
discovery teams (medicinal chemistry, endocrinology and oncology
research, pharmacogenomics and genetics) and also be responsible for
overseeing external research partnerships and collaborations.
Dominique Bridon, 49, is a graduate, from the Ecole Nationale
Superieure de Chimie and joined the laboratory of Nobel Laureate Sir
Derek Barton at Institut de Chimie des Substances Naturelles at Gif
sur Yvette (France) where he was awarded a Doctorate in Science. For
his post doctoral studies in organic chemistry, he moved to the
University of California Berkeley with Pr. William Dauben.
His professional career started in 1989 at Abbott Laboratories
within the Diagnostics Division; he was also associated with
Bioinformatic Venture and Peptide Engineering. In 1997, he joined the
start-up company Conjuchem in Montreal as V-P Research and Chief
Technology Officer. While at Conjuchem, Dominique originated the
discovery and development of in situ conjugates as a mean to achieve
controlled release of peptides and proteins. More recently, he served
as a member on the Board of Directors and on the Scientific Board of
Directors for several start-up companies; he has also been an advisor
to several biotech companies and venture capital funds.
About Ipsen
Ipsen is a European pharmaceutical group with over 20 products on
the market and a total worldwide staff of nearly 4,000. The company´s
development strategy is based on a combination of products in targeted
therapeutic areas (oncology, endocrinology and neuromuscular
disorders) which are growth drivers, and primary care products which
contribute significantly to its research financing. This strategy is
also supported by an active policy of partnerships. The location of
its four R&D centres (Paris, Boston, Barcelona, London) gives the
Group a competitive edge in gaining access to leading university
research teams and highly qualified personnel. In 2007, Research and
Development expenditure was EUR 185 million, in excess of 20% of
consolidated sales, which amounted to EUR 920.5 million while total
revenues amounted to EUR 993.8 million (in IFRS). More than 700 people
in Research & Development are dedicated to the discovery and
development of innovative drugs for patient care. Ipsen´s shares are
traded on Segment A of Eurolist by EuronextTM (stock code: IPN, ISIN
code: FR0010259150). Ipsen´s shares are eligible to the "Service de
Reglement Differe" ("SRD") and the Group is part of the SBF 120 index.
For more information on Ipsen, visit our website at www.ipsen.com.
Ipsen Forward-looking statements
The forward-looking statements and targets contained herein are
based on Ipsen´s management´s current views and assumptions. Such
statements involve known and unknown risks and uncertainties that may
cause actual results, performance or events to differ materially from
those anticipated herein. The targets contained herein were prepared
without taking into account external growth assumptions, which may
alter the parameters. These targets are based on data and assumptions
regarded as reasonable by the Group and depend on conditions or facts
likely to happen in the future, and not exclusively on historical
data. Actual results may depart significantly from the targets given
the occurrence of certain risks and uncertainties. The Group does not
commit nor gives any guarantee that it will meet the targets mentioned
above. Moreover, the Research and Development process involves several
stages at each of which there is a substantial risk that the Group
will fail to achieve its objectives and be forced to abandon its
efforts in respect of a product in which it has invested significant
sums. Therefore, the Group cannot be certain that favourable results
obtained during pre-clinical trials will be confirmed subsequently
during clinical trials, or that the results of clinical trials will be
sufficient to demonstrate the safe and effective nature of the product
concerned. Moreover, the targets described in this document were
prepared without taking into account external growth assumptions,
which may alter these parameters. These targets are based on data and
assumptions regarded as reasonable by the Group. These targets depend
on conditions or facts likely to happen in the future, and not
exclusively on historical data. Actual results may depart
significantly from these targets given the occurrence of certain risks
and uncertainties. The Group does not commit nor gives any guarantee
that it will meet the targets mentioned above. Ipsen expressly
disclaims any obligation or undertaking to update or revise any
forward looking statements, targets or estimates contained in this
press release to reflect any change in events, conditions, assumptions
or circumstances on which any such statements are based, unless so
required by applicable law. Ipsen´s business is subject to the risk
factors outlined in its information documents filed with the French
Autorite des Marches Financiers.
